Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials

JAMA

Volumn 297, Issue 15, 2007, Pages

  Bridge, Jeffrey A ^b   Iyengar, Satish ^a,c   Salary, Cheryl B ^a   Barbe, Rémy P ^a,d   Birmaher, Boris ^a   Pincus, Harold Alan ^e,f   Ren, Lulu ^c,g   Brent, David A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e New York Presbyterian Hospital ^*  (United States)

^f RAND CORPORATION   (United States)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGE DISTRIBUTION; ANXIETY DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REGISTER; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOCIAL PHOBIA; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34247365352     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.15.1683     Document Type: Review

References (76)

1. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332-339.
2. US Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads- Review.pdf. Accessed January 10, 2005.
3. Posner K, Oquendo M, Stanley B, Gould M. Suicidality classification project. http://www.fda.gov/ohrms/dockets/ac/04/slides/4006S1_08_Posner_files/ frame.htm. Accessed February 19, 2007.
4. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-1037.
5. March J, Silva S, Petrycki S, et al; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807-820.
6. Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004;43:1387-1396.
7. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998;280:1752-1756.
8. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001;40:773-779.
9. Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001;40:222-229.
10. The Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessivecompulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292:1969-1976.
11. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344:1279-1285.
12. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42:415-423.
13. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebocontrolled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61:1153-1162.
14. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40:762-772.
15. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003;290:1033-1041.
16. Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45:709-719.
17. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006;16:59-75.
18. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288.
19. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161:1079-1083.
20. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341-1345.
21. MHRA Committee on Safety of Medicines Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitor antidepressants. http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472. pdf. Accessed June 15, 2005.
22. MHRA Committee on Safety of Medicines Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. http://www.mhra.gov.uk/home/idcplg? IdcService=SS_GET_PAGE&ssTargetNodeId=221&useSecondary= true&ssDocName=CON019494&showpage=1. Accessed February 27, 2006.
23. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:791-795.
24. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205-1215.
25. von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26:311-315.
26. Emslie GJ, Findling RL, Rynn MA, Marcus RN. Efficacy and safety of nefazodone in the treatment of adolescents with major depressive disorder [abstract]. J Child Adolesc Psychopharmacol. 2002;12:299.
27. Dubitsky GM. Review and evaluation of clinical data: placebo-controlled antidepressant studies in pediatric patients. http://www.fda.gov/OHRMS/DOCKETS/ ac/04/briefing/2004-4065b1-08-TAB06-Dubitsky-Review.pdf. Accessed January 10, 2005.
28. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46:735-754.
29. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of 2 placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. In press.
30. Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1431-1438.
31. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158:2008-2014.
32. Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry. 2007;164:290-300.
33. Tourian KA, March JS, Mangano RM. Venlafaxine ER in children and adolescents with SAD. Paper presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
34. March JS, Entsuah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. In press.
35. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1992;31:1062-1069.
36. Braconnier A, Le Coent R, Cohen D, Group DS. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2003;42:22-29.
37. Paroxetine Study 453 A 38-week, two phase, multicenter study to investigate the safety and effectiveness of paroxetine (10-60 mg/day) in the treatment of children and adolescent outpatients with obsessive-compulsive disorder. http://www.gsk.com/media/paroxetine/ocd_453_full.pdf. Accessed November 6, 2005.
38. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull. 1997;33:149-154.
39. Black B, Uhde TW. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1994;33:1000-1006.
40. Meyer WJ III, Robert RWT, Rosenberg L, et al. Double blind placebo controlled study of acute stress disorder (ASD). Paper presented at: American Academy of Child and Adolescent Psychiatry; October 19-24, 2004; Washington, DC.
41. Glod CA, Lynch A, Berkowitz C, Hennen J, Baldessarini RJ. Bupropion versus citalopram versus placebo in adolescents with major depression. Paper presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
42. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol. 1992;45:255-265.
43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
44. Hedges LV. Estimation of effect size from a series of independent experiments. Psychol Bull. 1982;92:490-499.
45. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd ed. New York, NY: Churchill Livingstone; 2000.
46. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309-1312.
47. Rosenthal R. Parametric measures of effect size. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:231-244.
48. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
49. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
50. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
51. US Food and Drug Administration. Review and Evaluation of Clinical Data-NDA: 20-152 S-032, nefazodone hydrochloride (Serzone). http://www.fda.gov/ cder/foi/esum/2004/20152s032_Serzone_clinical_BPCA_FIN.pdf. Accessed March 9, 2006.
52. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd ed. Washington, DC: US Government Printing Office; 1976. DHEW publication 76-388.
53. Poznanski E, Mokros H. Children's Depression Rating Scale-Revised (CDRS-R). Los Angeles, Calif: Western Psychological Services; 1995.
54. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry. 1989;46:1012-1016.
55. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
56. Walkup J, Davies M. The Pediatric Anxiety Rating Scale (PARS): a reliability study. Paper presented at: 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 19-24, 1999; Chicago, Ill.
57. Eli Lilly and Co. Summary ID#236: clinical study summary: study B1Y-MC-HCCJ. http://www.lillytrials.com/results_files/prozac/prozac_summary_236. pdf. Accessed December 20, 2005.
58. US Food and Drug Administration. NDA 20-415 SE5-011: Mirtazapine pediatric supplement. http://www.fda.gov/CDER/foi/esum/2004/ 20415SE5_011_Mirtazapine%20MO%20ReviewFIN.pdf. Accessibility verified March 9, 2007.
59. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16:159-169.
60. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004;158:773-780.
61. Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45:1427-1439.
62. Donnelly CL, Wagner KD, Rynn M, et al. Sertraline in children and adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:1162-1170.
63. March JS, Klee BJ, Kremer CM. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Adolesc Psychopharmacol. 2006;16:91-102.
64. Mayes TL, Tao R, Rintelmann JW, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr. 2007;12:147-157.
65. Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998;55:56-64.
66. Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. JAMA. 1999;281:1707-1713.
67. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
68. Kraemer HC, Robinson TN. Are certain multicenter randomized clinical trial structures misleading clinical and policy decisions? Contemp Clin Trials. 2005;26:518-529.
69. Kaizar EE, Greenhouse JB, Seltman H, Kelleher K. Do antidepressants cause suicidality in children? a Bayesian meta-analysis. Clin Trials. 2006;3:73-98.
70. DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292:1363-1364.
71. Bridge JA, Barbe RP, Birmaher B, Kolko DJ, Brent DA. Emergent suicidality in a clinical psychotherapy trial for adolescent depression. Am J Psychiatry. 2005;162:2173-2175.
72. Apter A, Lipschitz A, Fong R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. J Child Adolesc Psychopharmacol. 2006;16:77-90.
73. Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry. 1995;152:673-682.
74. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804-814.
75. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull. 2006;132:132-149.
76. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2005;(4):CD004690. doi:10.1002/14651858.CD004690.pub2.